Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mavacamten in symptomatic obstructive hypertrophic cardiomyopathy
NCT02842242Phase 2Completed
- Sponsor
- MyoKardia
- Start
- Aug 2016
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mavacamten in hypertrophic cardiomyopathy (HCM), sponsored by MyoKardia. Primary endpoint: Change in Post-exercise Peak Left Ventricular Outflow Tract Gradient From Baseline to Week 12. Started Aug 2016; status: completed.
02
Drugs
mavacamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT02842242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02842242.